Human islets induce an injurious clotting reaction at the time of transplantation. A potential strategy to counteract this reaction would be to allow the islets to express hirudin, a protein with direct anticoagulative activity. Human islets were transduced with an adenoviral vector encoding hirudin, an empty corresponding vector, or left untreated. Islet culture supernatants were analyzed for hirudin using an ELISA, a chromogenic substrate assay based on the thrombin-binding properties of hirudin and in a whole blood viscosimetry assay. Immunohistochemical evaluation and determination of hirudin content revealed an abundant expression of hirudin after transduction. Hirudin content in transduced islets was in the range of the insulin content levels. A delay in human whole blood clotting time could be observed after addition of supernatants taken from islet cultures expressing hirudin. However, transduced islets showed an impaired glucose-stimulated insulin release, but could readily be retrieved 6 weeks after transplantation to athymic mice. A marked expression and secretion of hirudin with functional capacity can be induced in human islets using an adenoviral vector. The impairment in glucose-stimulated insulin release in hirudin-secreting islets, compared to controls, indicates that the additional protein synthesis affects the functional capacity of the islets.
INTRODUCTION
lets has been successful in several reports, but to date few studies have included functional proteins (1, 4, 11) . Naturally occurring hirudin is a low molecular weight We have previously reported that isolated human islets, when exposed to whole human blood in vitro, elicit (ϳ7 kDa) polypeptide produced in the salivary glands of the leech Hirudo medicinalis. Its anticoagulant activity an instant blood-mediated inflammatory reaction (IBMIR) (2). The effects of this acute inflammatory reaction comes from the chemical ability to inhibit thrombin, a serine protease catalyzing the final step in the blood co-could provide a reasonable explanation for early loss of islet mass after islet transplantation and thereby the need agulation cascade. Hirudin has many advantages over the commonly used anticoagulants such as heparin (e.g., of islets from more than one donor. IBMIR is characterized by platelet consumption and activation of the coag-hirudin does not interact with other blood proteins and, unlike heparin, can act upon bound thrombin). Hirudin's ulation and complement systems. Recent studies have shown that IBMIR is triggered by tissue factor (TF), small size and lack of necessary posttranslation modifications makes it a simple protein to express in adenovi-produced and secreted by the endocrine cells of the islets of Langerhans (7). Considering the current deficit of ral vectors, in comparison to heparin whose polysaccharide structure makes it impossible for cloning into the pancreata available for islet isolation, preventing IBMIR may prove a valuable strategy in the effort to reduce the viral vectors. As a means to reduce IBMIR, we have in this study number of islets needed to achieve insulin independence, and thereby allowing for an increased number of examined the possibility to induce synthesis and secretion of biologically active anticoagulant hirudin in hu-patients to benefit from this therapy. Because coagulation is central in IBMIR, a conceivable strategy to pre-man islets using an adenoviral vector. We demonstrate that human islet expression and secretion of hirudin re-vent this process would be to induce islet expression of suitable transgenes using viral vectors. Gene transfer of sults in a delay in clotting time in human blood in vitro, although the induced protein synthesis appeared to, at different proteins using adenoviral vectors to human is-760 CABRIC ET AL. least transiently, to reduce the capacity of the islets to adenoviral vector Av3HHV1 (2.6 × 10 10 pfu/ml; n = 10) or Av3null (6.5 × 10 10 pfu/ml; n = 3), and incubated for respond to glucose stimulation. 1 h in 500 µl of serum-free medium before medium sup-
MATERIALS AND METHODS
plemented with human AB serum was added. During Human Islet Isolation and Culture the different experiments, control islets not exposed to adenoviral vector were treated in the same way as the The pancreata were obtained from 10 normoglycemic corresponding transduced islets. human donors, after appropriate consent for multiorgan donation. Human islets of Langerhans were isolated at Quality Test the Division of Clinical Immunology at the University To examine whether the transduction of the islets of Uppsala, using a modification of previously described with Av3HHV1 had any adverse effect on islet function, semiautomated digestion-filtration method (3,6,8), folthe quality of the islets was assessed in terms of insulin lowed by purification on a continuous density gradient secretion in response to a glucose stimulation in a dyin a refrigerated COBE 2991 centrifuge (COBE Blood namic perfusion system between days 4 and 7 and days Component Technology, Lakewood, CO, USA).
14 and 16 after transduction (n = 5). To evaluate the ef-The islet preparations were of good quality but were fects of the transduction procedure itself, islets were also available for experimental use because the total islet volincubated with Av3null vector carrying no transgene ume was too low for clinical transplantation. Islet vol-(n = 3; evaluation on days 6 and 9 after transduction). ume and purity were determined by microscopic sizing Islets were challenged with two glucose concentrations on a grid after staining with diphenylthiocarbazone. The (initially in 1.67 mmol/L, thereafter in 16.7 mmol/L glupurities of the islet preparations varied between 70% and cose, and finally back to 1.67 mmol/L). Fractions were 90%.
collected with 6-min intervals during 120 min. Concen-The islet preparations were placed in untreated petri trations of insulin were analyzed with a commercial dishes Sterilin (Tamro Med. Lab. AB) and kept at 37°C ELISA kit (Mercodia). Values are given as pmol/L. in a atmosphere of 5% CO 2 in humidified air in culture medium, CMRL 1066 (GIBCO BRL, Invitrogen) sup-Measurement of Soluble Hirudin Using ELISA plemented with 10 nM nicotinamide (Sigma Chemicals),
Blocking solution (1% BSA in PBS) of 250 µl was 10 mM HEPES buffer (GIBCO BRL, Invitrogen), 0.25 incubated for 1 h at room temperature in micro-test µg/ml fungizone (GIBCO BRL, Invitrogen), 50 µg/ml wells that were precoated with 150 µl sheep-anti-hirudin gentamicin (GIBCO BRL, Invitrogen), 2 mM L-glutapolyclonal antibody (Affinity Biologicals Inc.) for antimine (GIBCO BRL, Invitrogen), 10 µg/ml Ciprofloxagen capture. Collected islet culture supernatants (100 µl) cin (Bayer), and 10% (v/v) heat-inactivated human sewere added and incubated for 1 h followed by an incurum. After transduction the islets were cultured for bation with 100 µl of the same sheep-anti-hirudin poly-14-16 days. In five isolations (culture supernatant clonal antibody conjugated to biotin. The subsequent inassays) samples of 1 ml islet supernatant were collected cubation for 15 min with 100 µl streptavidin-conjugated on days 1-7, 9, 12, and 14. Additional medium of 1 ml horseradish peroxidase (HRP; Amersham Biosciences, supplemented with serum was added after each sam-UK) completed the formation of the antibody-enzyme pling, except days 7 and 14, when medium was comcomplex, which was developed by adding 100 µl TMB pletely changed. In another five isolations (immunohissubstrate. The reaction was stopped after 5 min with 100 tochemistry, protein/DNA content experiments) medium µl 1 M H 2 SO 4 . After each incubation time the wells were was changed every second day.
washed three times with wash buffer (PBS, 0.05%
Adenoviral Vectors and Transduction Procedures
Tween 20). The hirudin levels were determined by measuring absorbance at a wavelength of 450 nm. A serial We used a replication defective E1, E2a, and E3 region-deleted adenoviral vector Av3HHV1, coding for dilution of known amount of recombinant hirudin (Re-fludan, Aventis Pharma) was run simultaneously to secretory hirudin cDNA, or Av3null vector carrying no transgene, generously provided by Novartis Pharma Re-create a standard curve. The background average of the blanks was deducted from the standards and sample search (Basel, Switzerland). The hirudin gene is inserted into the deleted E1 region under the control of Rous readings. sarcoma virus promoter (RSV) as previously described Chromogenic Substrate Assay (5). At the time of transduction, the islets were sedimented by light centrifugation (1000 rpm for 60 s) and
For the chromogenic hirudin determination a thrombin binding-based assay was used (Chromogenix, Möln-then washed in serum-free culture medium, M199 Earl's salt (GIBCO BRL, Life Technologies). Then 10 µl of dal, Sweden). Incubation of collected samples of islet culture supernatants with an excess of human thrombin islets (1 µl = 500 IEQ) was transduced with 10-20 µl of results in rapid complex formation between hirudin pres-of the homogenate was used for measurement of hirudin concentration by ELISA as described above. ent in the supernatant and thrombin. The inhibited thrombin activity is proportional to the amount of hirudin present in the sample. The remaining amount of throm-Transplantation of Transduced and Untreated Islets to C57BL/6J (nu/nu) Mice bin hydrolyses the chromogenic substrate S-2366, thus liberating the chromophoric group, pNA. The color is Adenoviral vector transduced and untreated islets then read photometrically at 405 nm. Islet culture superwere simultaneously transplanted as separate grafts to natant (50 µl) sample was incubated for 2-3 min at C57b1/6J nude (nu/nu) athymic mice under the left kid-37°C with 100 µl human thrombin. Subsequently, 100 ney capsule as previously described (9). In total five µl of the chromogenic substrate S-2366 was added and mice were transplanted. All mice were transplanted with incubated for exactly 3 min. The reaction was stopped two islet grafts, one composed of transduced islets and with 20% citric acid, and the change in absorbance was one of untreated islets from the same isolation. After 5 measured at 405 nm. A calibration curve was constructed weeks, the animals were killed and the grafts were harusing medium containing recombinant hirudin (Refluvested with margin of 5 mm of adjacent kidney tissue dan) to obtain final concentrations between 0.019 and and prepared for cryosectioning and immunohistological 0.2 µg/ml. evaluation in light microscope.
Measurement of Clotting Time Using a Free Immunohistochemistry Oscillating Rheometer
Intact human islets and transplanted graft biopsies Whole blood drawn into citrate tubes (Vacutainer TM ) were snap frozen in precooled isopentane and subsewas taken from healthy volunteers that had received no quently stored at −70°C. Serial sections, 6-7 µm thick, medication for at least 14 days. Clotting time in whole were cut in a cryostat (−20°C), air dried, fixed in 100% blood with addition of islet culture supernatants taken cold acetone, and stored at −70°C. Islet sections were day 7 (n = 5) was measured in a four-channel free oscilstained with polyclonal sheep anti-hirudin (Affinity Biolating rheometer (ReoRox 4, Global Haemostasis Instilogicals Inc.), and sections from the transplanted grafts tute AB, Linköping, Sweden). As a control we used were stained with guinea pig anti-insulin (DAKO, Carculture supernatants from untreated islets. The free ospinteria, CA, USA). After storage, the slides were cillating rheometer used in this study has four measuring washed in PBS and incubated in 0.6% H 2 O 2 in PBS to channels embedded in an aluminum block thermostat inhibit endogenous peroxidase. Subsequently, 15-min with temperature control. In our experiment the temperincubations with normal rabbit serum to prevent nonspeature was set at 37°C. Each measuring channel harbors cific background staining were preformed on islet seca cylindrical, 12-mm-diameter plastic sample cup. For tions before the slides were incubated with the primary each measurement 100 µl sample, 1 ml whole blood, antibody. Transplanted graft sections were incubated and 22 µl 1 M CaCl 2 was used for each cup, which was with the primary antibody overnight at 37°C. After incuplaced on a hollow shaft connected to the base of the bation with primary antibody islet sections were incuinstrument. Every 6 s, the cup was set into free horizonbated with rabbit anti-goat Ig antibody (cross-reactive tal oscillation around its vertical axis, and the damping with sheep Ig; code No. Z0228; DAKO). Subsequent and frequency of the oscillation was registered. Clotting incubations of the sections with secondary antibodies times were identified by the software program of the were performed sequentially for 30 min, followed by instrument as the point of maximal damping. three washes for 5 min in PBS between each step. After a final incubation of islet sections with goat PAP reagent Insulin, Hirudin, and DNA Contents of Islets (code No. B0157; DAKO) and graft sections with goat anti-rabbit Envision Ig antibody (code No. K4002; Islets in groups of 100 were homogenized by ultra-DAKO), the alkaline phosphatase reaction was develsonic disruption in 300 µl phosphate-buffered saline oped using AEC Substrate Chromogen (code No. K3464; containing 5 mM EDTA, 10 mM benzamide, 0.1 mg/ml DAKO) for 15 min. The slides were thereafter counterof soybean trypsin inhibitor, and 1 mM PMSF (n = 5). stained with Mayer's hematoxylin and mounted in glyc-A fraction of the homogenate was mixed with acid ethaerin gelatin. The islets and transplanted graft biopsies nol and insulin was extracted overnight at 4°C. The inwere thereafter analyzed under a light microscope. sulin concentration of the extract was measured with a commercial ELISA kit (Mercodia). Values are given as Statistics pmol/L. Another fraction of the homogenate was used for DNA measurement using commercial PicoGreen All results are presented as mean ± SEM. The Student's paired t-test was used to compare paired data (hir-dsDNA Quantitation Reagent and Kits. A third fraction udin-expressing islets and controls) in different islet iso-hirudin was added to culture medium to obtain final concentrations between 0.02 and 0.2 µg/ml, respectively. lations.
The curve was linear over the entire concentration range.
RESULTS
Hirudin expression showed a similar pattern as seen after the ELISA analysis. A plateau level of hirudin was Hirudin Content in the Culture Supernatant (ELISA) reached after day 5, although the levels were 30-40% In all experiments, transduction resulted in hirudin lower compared to the ELISA analysis. The results are expression (n = 5). After 3 days of culture hirudin expresented as mean level of hirudin (ng/ml) ± SEM (n = pression was first detected, gradually increased, and 5) ( Fig. 1B) . reached plateau levels 6-7 days after transduction. A decrease was observed after day 7 as a consequence of Insulin, Hirudin, and DNA Content a total medium change. The results are presented as
In the five different isolations the level of hirudin/ mean level of hirudin (ng/ml) ± SEM (n = 5) ( Fig. 1A) .
DNA content was found to be comparable or higher than the insulin/DNA content levels. At the same time the Chromogenic Substrate Assay insulin/DNA levels in the transduced islets were found In all experiments, transduction resulted in expresto be lower (p < 0.05) compared to untreated control ission of hirudin (n = 5). Transduction efficiency of Av3lets (2.86 ± 0.9 and 4.56 ± 1.6, respectively). The results HHV1-treated human islets was assessed at 72 h after are presented as mean level of insulin or hirudin (pmol/ gene transfer. To obtain a reference curve recombinant µg DNA) ± SEM (n = 5) (Fig. 2) .
Immunohistochemical Staining of Islets After Transduction
Immunohistochemical staining of frozen and sectioned islets from five different isolations on day 7 after transduction showed hirudin expression in a majority of the islet cells, both in the core and in the periphery (Fig.  3A) . Parallel experiments with untreated control islets were all negative (not shown).
Graft Survival of Islets Transduced With Adenoviral Vector and Untreated Controls in nu/nu Mice
After 5 weeks the grafts were harvested and processed for immunohistochemistry (transduced islets, n = 5; control islets, n = 5). The morphology indicated successful engraftment and survival of both transduced ( Fig. 3B ) and untreated islets (not shown).
Measurement of Clotting Time Using Free Oscillating Rheometer
As shown in the diagram, islets transduced with Av3-HHV1 secreted hirudin in quantities large enough to be detected in the ReoRox assay. A 2.2 ± 0.4-min (29.0 ± 6.2%; p < 0.05) delay in clotting time in human whole blood was observed after addition of supernatants taken from Av3HHV1 transduced islets. Corresponding untreated islet supernatants were used to obtain reference tors) and untreated islets responded to glucose stimula- tion. However, relative to the two types of control islets, ing a replication defective adenoviral vector. The ability of the hirudin vector to induce synthesis of hirudin in the hirudin-secreting islets had an impaired insulin secretion capacity. The results are presented as mean level the islets was tested using two independent techniques: a chromogenic substrate assay and an ELISA. The chro-of insulin (pmol/L) ± SEM (n = 5 and n = 3) (Figs. 5 and 6). mogenic substrate assay measures the level of functional thrombin-binding hirudin present in the sample while DISCUSSION the ELISA shows the total amount of hirudin present. This could explain why the chromogenic substrate assay As a conceivable strategy to reduce IBMIR, we demonstrated that expression of biologically active hirudin indicated slightly lower levels of hirudin in comparison to the ELISA method. After 3 days of culture, following can be induced in intact human islets of Langerhans us- the transduction, hirudin was first detected and the levels taken from Av3HHV1 transduced islets in comparison to their corresponding controls. An increase in clotting then gradually increased and reached plateau levels after 6-7 days. A delay in clotting time of approximately time together with a hirudin content comparable to the insulin content in transduced islets indicates that sys-30% could be observed in 1 ml of human whole blood with addition of 100 µl of islet culture supernatants temic effects may be observed in transplanted patients. However, while severe systemic effects could be mini-when used in the clinic is that, in rare cases, patients who have been preexposed to the drug, especially within mized, the microenvironment around the islets will still create a substantial concentration gradient that will in-recent months, have an increased risk of developing severe anaphylactic reactions. Forthcoming experiments in hibit coagulation and clot formation in the immediate vicinity of the islets. large-animal models will demonstrate if hirudin alone is able to control IBMIR in vivo or whether the thrombin Expression of biologically active hirudin from human islets may contribute to a marked graft protective effect.
inhibitor should be combined with some additional drug. Further, the islet protective effect after transduction Hirudin not only prevents the terminal step of coagulation, the fibrin formation, but also inhibits other throm-should be compared with that achieved applying systemic blockade of coagulation. bin-catalyzed reactions, such as the activation of factors V, VIII, and XIII and platelet activation. The direct in-Islets were exposed to low and high glucose levels in order to examine whether the insulin secretion from the hibitory action of hirudin on thrombin has valuable therapeutic potential as an anticoagulant. Although heparin islets was affected after transduction with adenoviral vectors. Both transduced and nonexposed islets responded is widely used as an anticoagulant, it cannot inactivate fibrin-bound thrombin, a major stimulus for thrombin to glucose stimulation, but a difference in capacity could be detected in favor of islets not expressing hirudin. growth. It also requires endogenous cofactors, such as antithrombin III. Furthermore, systemic administration
The level of hirudin content was found to be comparable or even higher than the insulin content levels, on of heparin may induce serious bleedings, and in rare occasions heparin-induced thrombocytopenia. In contrast, both a total amount and a molar comparison. The insulin levels in the hirudin-secreting islets were found to be hirudin inhibits thrombin directly, both in the free and in the thrombus-bound state, and does not require any lower compared to untreated control islets. Taken together this indicates that the additional protein synthesis endogenous cofactors. Moreover, it does not induce a high degree of bleeding when administrated to animals induced may have affected the capacity of producing insulin and may also provide an explanation for the ob-or humans (10) . The main disadvantage with hirudin served impaired glucose response in hirudin-secreting possibility to use adenoviral vectors to induce expression of protective proteins in human islets as a mean to islets. This explanation is supported by the fact that islets exposed to empty vector had a normal function, thus prevent IBMIR. This study demonstrates that the adenoviral transduction may interfere with the insulin produc-not suggesting that the transduction procedure itself had an influence on the insulin-secreting capacity. In this tion in the islets and that a balance between transgene expression and islet function after transduction will have context it should however be noted that while only the β-cells express insulin, hirudin is likely to be expressed to be determined in order to obtain optimal islet graft function after transplantation. also in other cell types within the islets and also in contaminating exocrine cells.
